ALK and Miyoshi myopathy: Additionally, MM cells treated with ALK inhibitors, including crizotinib, ceritinib, and alectinib, demonstrated a concentration-dependent reduction in cell viability in concentrations that are in the range (3.1–11.29 μM) measured in serum from patients [39, 40], affecting both proteasome-sensitive and resistant cells.